ARTTIC

ARTTIC S.A.S.

ARTTIC assists clients from all business and research sectors, small and large, private and public, to ensure the success of their collaborative research and innovation ventures. During close to 30 years of success, ARTTIC developed and demonstrated expertise in the set-up and management of more than 300 large-scale ambitious projects. Based on its long-standing experience in a range of funding programmes across scientific and technological domains, ARTTIC helps clients to move from strategic plans to effective competitive research and development of innovative solutions, resulting in successful applications and high-performance businesses.


Founded in Paris in 1987, ARTTIC is now a group of companies with main offices in France (Paris and Toulouse), Germany (Munich and Berlin), Belgium (Brussels), England (Derby) and Israel (Tel Aviv). In 2015, ARTTIC has been ranked first SME in Europe by the European Commission considering the number of grant agreements signed by ARTTIC.

 

For more information, please visit our website.

 

Project Manager: Dr. Claudia Pfander (Consultant)

Project Leader: Annette Ringwald (Senior Consultant)

Axxam

Axxam SpA

AXXAM SpA is a privately owned innovative Partner Research Organization (iPRO) and discovery company located at OpenZone Science Park, Bresso (Milan, Italy), with chemistry laboratories located in Naples (Italy) and business development offices in Europe, US and Japan.

Since its inception in 2001, as a spin-off from the Bayer Group, Axxam has built up an integrated discovery “Lead Engine” platform, consisting of assay development, high throughput screening and hit follow-up activities and has supported the discovery programs of its clients by providing excellent quality discovery services carried out by highly engaged experts.

Axxam has a multi-year proven track record as a discovery services partner for the life science industry. Until now, Axxam has collaborated with over 50 international partners, ranging from small biotechs to big pharma, agrochemical, fragrance and flavour companies, and a growing network of research institutions and academic groups.

 

For more information, please visit our website.

 

Project Leader: Dr. Paola Tarroni (Research Portfolio Management)

Life and Brain

Life & Brain GmbH

LIFE & BRAIN is the commercial hub of the Medial Center at the University of Bonn. As an SME founded in 2002 our mission is to discover and develop novel strategies for the diagnosis and therapy of nervous system disorders. Integrating a unique set of expertise in Genomics, Transgenics, Cellomics and NeuroCognition, we aim at delivering the next generation of products for disease modeling and prediction, compound development and tissue regeneration.

LIFE & BRAIN Cellomics offers authentic cellular disease models that contribute to drug discovery and regenerative medicine. A particular focus of the Cellomics Platform is the controlled differentiation of human pluripotent stem cells into defined cell types of the nervous system. We offer custom development services for phenotyping and assay development for research purposes and drug screening. Extensive cell culture automation enables robust production of hiPS cell-based disease models on industrial scale and standards. Genomic quality control service can be provided via our Genomics department.

 

For more information, please visit our homepage.

 

Project Leader: Oliver Bruestle (CEO)
Project Leader: Simone Haupt (Head of Bioengineering)

Home
Menu
Top
 

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115976. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies.

Social Media

PHAGO by Twitter PHAGO by LinkedIn

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115976. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies.